Generation of mouse models for type 1 diabetes by selective depletion of pancreatic beta cells using toxin receptor-mediated cell knockout  by Matsuoka, Kunie et al.
Biochemical and Biophysical Research Communications 436 (2013) 400–405Contents lists available at SciVerse ScienceDirect
Biochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate /ybbrcGeneration of mouse models for type 1 diabetes by selective depletion
of pancreatic beta cells using toxin receptor-mediated cell knockout0006-291X  2013 The Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.bbrc.2013.05.114
⇑ Corresponding author at: Mammalian Genetics Project, Department of Genome
Medicine, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa,
Setagaya-ku, Tokyo 156-8506, Japan. Fax: +81 3 5316 3311.
E-mail address: matsuoka-kn@igakuken.or.jp (K. Matsuoka).
1 Present address: Division of Regenerative Medicine, TES Holdings Co., Ltd, Japan.
2 Present address: Laboratory of Embryonic Stem Cell Research, Institute for
Frontier Medical Science, Kyoto university, Japan.
Open access under CC BY license.Kunie Matsuoka a,e,⇑, Michiko Saito b,e, Kosuke Shibata c, Michiko Sekine c, Hiroshi Shitara c, Choji Taya c,
Xiaohong Zhang d,1, Tsuneo A. Takahashi d,2, Kenji Kohno b,e, Yoshiaki Kikkawa a, Hiromichi Yonekawa c,e
aMammalian Genetics Project, Department of Genome Medicine, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan
bGraduate School of Biological Sciences, Nara Institute of Science and Technology, 8916-5, Takayama, Ikoma, Nara 630-0192, Japan
c Laboratory for Transgenic Technology, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan
dDivision of Cell Processing, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
eBio-oriented Technology Research Advancement Institution (BRAIN), 1-40-2, Nisshin, Kita-ku, Saitama 331-8537, Japan
a r t i c l e i n f oArticle history:
Received 21 May 2013






Xenogeneic transplantationa b s t r a c t
By using the toxin receptor-mediated cell knockout (TRECK) method, we have generated two transgenic
(Tg) murine lines that model type 1 (insulin-dependent) diabetes. The ﬁrst strain, C.B-17/Icr-Prkdcscid/
Prkdcscid-INS-TRECK-Tg, carries the diphtheria toxin receptor (hDTR) driven by the human insulin gene
promoter, while the other strain, C57BL/6-ins2(BAC)-TRECK-Tg, expresses hDTR cDNA under the control
of the mouse insulin II gene promoter. With regard to the C.B-17/Icr-Prkdcscid/Prkdcscid-INS-TRECK-Tg
strain, only one of three Tg strains exhibited proper expression of hDTR in pancreatic b cells. By contrast,
hDTR was expressed in the pancreatic b cells of all four of the generated C57BL/6-ins2(BAC)-TRECK-Tg
strains. Hyperglycemia, severe ablation of pancreatic b cells and depletion of serum insulin were
observed within 3 days after the administration of diphtheria toxin (DT) in these Tg mice. Subcutaneous
injection of a suitable dosage of insulin was sufﬁcient for recovery from hyperglycemia in all of the exam-
ined strains. Using the C.B-17/Icr-Prkdcscid/Prkdcscid-INS-TRECK-Tg model, we tried to perform regenera-
tive therapeutic approaches: allogeneic transplantation of pancreatic islet cells from C57BL/6 and
xenogeneic transplantation of CD34+ human umbilical cord blood cells. Both approaches successfully res-
cued C.B-17/Icr-Prkdcscid/Prkdcscid-INS-TRECK-Tg mice from hyperglycemia caused by DT administration.
The high speciﬁcity with which DT causes depletion in pancreatic b cells of these Tg mice is highly useful
for diabetogenic research.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction DT to TRECK-Tg mice causes depletion in hDTR expressing cellsConditional in vivo depletion of lineage-speciﬁc cells can be
achieved through administration of diphtheria toxin (DT) to
TRECK-Tg mice that carry a human diphtheria toxin receptor
(hDTR) cDNA transgene driven by a tissue-speciﬁc promoter. Un-
like conditional knockout mice, cell depletion is initiated by DT
administration; therefore, the effects of the depletion can be
observed in the same Tg strain by comparing cohorts pre- and
post-administration of DT [1]. Moreover, the administration ofand therefore speciﬁcally eliminates these cells without eliciting
an inﬂammatory response. We succeeded in generating the ﬁrst
TRECK-Tg mouse model for the speciﬁc ablation of hepatocytes
in the mouse liver under the control of the albumin promoter
[2]. This technique has been successfully applied to generate sev-
eral models for human diseases [2–4] and has revealed several pre-
viously unknown in vivo cellular functions [5,6].
Type 1 diabetes (T1D) is a major disease that has garnered con-
siderable attention for both children and young adults. T1D is a se-
vere autoimmune disease, and its onset is known to be caused by
an immunological destruction of pancreatic b cells, the insulin-pro-
ducing islet cells [7]. In humans and mice, the etiology of T1D,
including the natural diabetogenic agents [8,9] and pathogenic
processes that result in T1D, has not been well characterized
[10–12]. By contrast, artiﬁcial diabetogenic procedures in mice,
e.g., alloxan- or streptozotocin-induced T1D models [13,14], are
well established, and these models have been widely used for
developing drugs for T1D and for pathogenic studies of diabetes-
related complications. However, the onset incidences in both
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breeding, etc. In particular, sex- [15] and/or strain differences
[16–19] strongly inﬂuence the incidence of onset. Therefore, it is
difﬁcult to establish optimal conditions for the onset of the allox-
an- or streptozotocin-induced T1D. Furthermore, side effects of
the drugs, including alloxan- or streptozotocin-induced nephropa-
thy [20] and streptozotocin-induced hepatopathy [21,22], are
severe and make model generation difﬁcult.
To overcome the drawbacks of drug-induced T1D models, we
generated the Tg mice expressing the hDTR under control of the
human INS and mouse ins2 promoters by the TRECK method [2].
hDTR is expressed exclusively on the surface of target cells in the
TRECK-Tg mice. Without administration of DT, the Tg mice main-
tain a healthy condition. Once DT is administered to the Tg mice,
the lineage of cells expressing hDTR is severely depleted. We have
successfully generated two lines of ins-TRECK-Tg mice with differ-
ent vectors or strains. These lines include C.B-17/Icr-Prkdcscid/
Prkdcscid (SCID)-INS-TRECK-Tg mice and C57BL/6 (B6)-ins2(BAC)-
TRECK-Tg mice. All of the Tg mice were hyperglycemic 3 days after
DT administration. Immunohistochemical analysis revealed that
hyperglycemia was caused by the depletion of pancreatic b cells.
Furthermore, hyperglycemia was cured by the administration of
insulin. Ultimately, our evidence supports that these TRECK-Tg
mice may be used to model T1D.2. Materials and methods
An expanded Section 2 is in the online data Supplementary
material
2.1. Construction of transgenes
2.1.1. Plasmid vector
Transgene was constructed, as shown previously [2], with the
1.9 kbp human insulin promoter region, rabbit b-globin intron,
human HB-EGF L148S/P149T mutant cDNA [23] and theFig. 1. Generation of a transgene for ins-TRECK-Tg mice. (A) Construct of a plasmid-bas
SphI/BamHI fragment of the human insulin (INS) promoter [2]. (B) Generation of a BAC-b
clone carrying the complete mouse ins2 gene (RP23-92L23) was replaced by the galK cass
hDTR cassette to ﬁnally obtain a recombinant hDTR BAC. Only the scaffold structures of th
by DT administration. Mice were intraperitoneally administered the indicated doses of DT
mice and their littermates, respectively. Values over 600 mg/dl, which is the upper limipolyadenylation signals of rabbit b-globin and SV40 (Fig. 1A). The
3.8 kbp DNA fragment was excised by double digestion with SphI
and XhoI and puriﬁed using the QIAquick gel extraction kit (QIA-
GEN, Valencia, CA, USA) and the Wizard DNA Clean-Up System
(Promega, Madison, WI, USA).
2.1.2. BAC vector
A recombinant BAC clone was generated using a recombineer-
ing method with galK selection [24]. A mouse BAC clone that con-
tained ins2 (RP23-92L23) was purchased from BACPAC Resources
Center, Children’s Hospital Oakland Research Institute (Oakland,
USA). To perform the ﬁrst replacement, the ins2 coding region in
RP23-92L23 was replaced by galK as previously described to gener-
ate BAC/galK. Then, the galK insert was replaced by the hDTR cDNA
to generate BAC/hDTR (Fig. 1B).
2.2. Transplantation of pancreatic islets from C57BL/6 mice
Langerhans islets were prepared from the C57BL/6 pancreas.
Brieﬂy, intraductal perfusion of pancreases was performed using
HBSS containing 1.5 mg/ml collagenase P (Roche, Indianapolis,
USA). Langerhans islets were separated by centrifugation using
Histopaque-1077 (Sigma–Aldrich, St. Louis, USA) and isolated by
hand picking under a dissecting microscope. Two hundred islets
were transplanted beneath the renal capsule.
2.3. Transplantation of human umbilical cord blood-derived cells
We have been approved the ethics committee of The Tokyo
Metropolitan Institute of Medical Science (approved no. 17-2-3)
and the Tokyo Cord Blood Bank (07-11-02) to use human umbilical
cord blood. Mononuclear cells in the cord blood were isolated on
Ficoll Paque (GE healthcare, Pittsburgh, USA) and processed further
to isolate CD34+ cells by using a magnetic cell sorter direct CD34
progenitor cell isolation kit (Miltenyi Biotech, Bergisch Gladbach,
Germany) according to the manufacturer’s instructions. Seven daysed transgene. The alb promoter of the original TRECK cassette was replaced with a
ased transgene. The DNA fragment from the ﬁrst exon to the poly(A) signal of a BAC
ette. The resultant recombinant BAC (RP23-92L23_rgalK) was replaced again by the
e BAC clones are shown. (C) Induction of hyperglycemia in SCID-INS-TRECK-Tg mice
at day 0. Then, blood glucose levels were measured. Tg and LM stand for transgenic
t of the blood glucose meters, were indicated as 600 mg/dl.
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jected intravenously with a total of 1–4  105 human cells and
were given 50 ll of anti-asialo GM1 antiserum (Wako Pure Chem-
ical Industries, Osaka, Japan) every 11 days to deplete NK cells.Fig. 2. Immunohistochemical study of the islets of SCID-INS-TRECK-Tg and WT
mice. (A) Hematoxylin-eosin staining (a and b) and immunostaining with an anti-
hDTR antibody (c and d). Panels a and c are pancreases of non-Tg mice and b and d
are those of Tg mice. Scale bars represent 100 lm. (B) Immunohistochemical
staining of pancreatic islets. The left panel is an islet from Tg mice that was not
administered DT and the right panel is after 7 days of administration of 5 lg/kg of
DT. The sections of pancreas were stained by anti-insulin (green) and anti-glucagon
(red) antibodies, respectively. Scale bars represent 50 lm.3. Results
3.1. DT-induced hyperglycemia
We obtained three Tg strains by direct injection of the plasmid
based TRECK-Tg cassettes into the pronucleus-eggs of SCID mice.
Only one of these Tg strains showed the desired phenotype of
DT-induced hyperglycemia. Therefore, we carried out further
experiments using the SCID-INS-TRECK-Tg #70 strain that
displayed a phenotype. By contrast, all of the B6-ins2(BAC)-
TRECK-Tg strains displayed DT-induced hyperglycemia, although
the sensitivity to DT varied among strains. We used #5 strain for
further experiments (Table 1). The Tg strains used here will be
deposited and available from RIKEN BioResource Center (Tsukuba,
Japan).
Dosages of 5 ng/kg, 50 ng/kg, 500 ng/kg, 5 lg/kg, 10 lg/kg,
20 lg/kg, and 50 lg/kg of DT was administered to SCID-INS-
TRECK-Tg mice, and their littermates (non-Tg mice) were given
5 lg/kg, 10 lg/kg, and 20 lg/kg of DT. Hyperglycemia was induced
in Tg mice administered over 50 ng/kg of DT. Non-Tg mice did not
display any elevation of blood glucose levels. Blood glucose was
elevated 2 days after DT administration and reached a higher level
(>600 mg/dl) than the upper limit of the blood glucose meters by
7 days. The elevation of blood glucose over the threshold for hyper-
glycemia (200 mg/dl) was maintained for 65 days after DT admin-
istration; however, little dose-dependency was observed (Fig. 1C).
All Tg mice administered over 50 ng/kg of DT were hyperglycemic
with blood glucose levels >200 mg/dl by 2 days after DT adminis-
tration, and their blood glucose levels were maintained at
>400 mg/dl for 50 days after DT administration.3.2. Histological and immunohistological analysis of pancreatic islets
Little or no morphological changes were observed with the
staining pancreatic islets from Tg mice with HE in comparison to
non-Tg mice (Fig. 2Aa and Ab). However, hDTR signals were ob-
served in the Tg mice when the pancreas of the Tg and non-Tg mice
were immunostained with anti-hDTR, the molecular nature and
in vivo function of which is the heparin-binding epidermal growth
factor (HB-EGF) (Fig. 2Ac and Ad). Pancreatic islets from Tg mice
were also immunostained with anti-insulin and anti-glucagon
antibodies (Fig. 2B). In the pancreatic islets of Tg mice without
DT administration, insulin-producing b cells preferentially occu-
pied in the islets. By contrast, administration of DT caused a drastic
decrease in the number of b cells, although the DT-induced deple-
tion of b cells was not complete. These results suggest that theTable 1
Summary of T1D phenotypes in C57BL/6-ins2(BAC)-TRECK-Tg mouse strains.
Strain no. 5 14 17 33
DT dose (lg/kg) 1 1 100 1
Plasma glucose (mg/dl) >600 >600 400–500 >600
Glycosuria +++ +++ ++ +++
Ketonuria +++ +++ + +++
Insulin dependency +++ +++ +++ +
Blood insulin level Low ND ND ND
Islet lesion +++ +++ ++ +++
ND, not done.DT-induced hyperglycemia is caused by depletion of pancreatic b
cells and consequently the deprivation of plasma insulin.
The morphology of pancreatic islets was not changed as
indicated by HE staining (Fig. 2A). However, morphological abnor-
mality was observed when the islets were immunostained with
anti-insulin and anti-glucagon antibodies (Fig. 2B). Although b cells
are surrounded by a cells in the islets of non-Tg mice (data not
shown), this structure was irregularly arranged in Tg mice. This
morphological abnormality was also observed in all INS-TRECK-
Tg mice and ins2(BAC)-TRECK-Tg mice. The reason for this abnor-
mality is currently unknown.
3.3. Decrease of plasma insulin and absence of glucose-induced
recovery of plasma insulin levels
The level of plasma insulin was markedly decreased by 5 days
after the administration of DT to the Tg mice. The serum insulin le-
vel was less than 2 ng/ml in Tg mice without DT administration
and non-Tg with/without DT administration. The insulin level of
Tg mice reached 0.26 ng/ml at 5 days after DT administration. This
level was not increased when 2 g/kg glucose was orally adminis-
tered. By contrast, DT administration did not affect the serum insu-
lin level of non-Tg mice, and the non-Tg mice demonstrated a
remarkably increased plasma insulin level of approximately 9 ng/
ml 10 min after glucose challenge (Fig. 3A). This result showed that
pancreatic b cells were functionally depleted by DT administration,
which is consistent with the morphological evidence that b cells
were depleted by the administration of DT to Tg mice (Fig. 2B).
Fig. 3. Insulin-dependent hyperglycemia in SCID-INS-TRECK-Tg mice. (A) SCID-INS-
TRECK-Tg mice and non-Tg littermates were administered 1 lg/kg of DT or PBS.
After 5 days, mice were orally administered 2 g/kg glucose. Serum insulin levels
were measured before and after 10 min of glucose treatment. (B) Tg mice and non-
Tg littermates were administered 5 lg/kg DT. After 7 days, mice were injected with
super short-acting insulin at doses of 400 mU/kg at 0 min and 4 U/kg at 100 min.
Mouse with severe hyperglycemia was injected with an additional 40 U/kg at
180 min. Arrows with a straight line indicate the time of injection and the arrow
with a dotted line shows the third injection time point for Tg mice with severe
hyperglycemia.
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The blood glucose levels of Tg mice with DT-induced hypergly-
cemia were temporally decreased with injection of superFig. 4. Hyperglycemia is cured by allogeneic and xenogeneic transplantation therapy. (
7 days after administration of 5 lg/kg of DT. The blood glucose levels of mice with trans
lines) were measured at the indicated time points. Values over 600 mg/dl, which is the u
section was stained with antibodies against insulin (green) and glucagon (red) and coun
fractionated from human umbilical cord blood cells were transferred intravenously into
indicated time points. Data have been expressed as mean ± SD. Statistical signiﬁcance wasshort-acting insulin; however, the efﬁcacy of the insulin action
was dependent on the severity of hyperglycemia. The ﬁrst injection
of 400 mU/kg insulin at 0 min did not cause any effect in both mild
and severe cases. The second injection of 4 U/kg at 100 min caused
a clear decrease of blood glucose in mice with mild hyperglycemia
within 30 min of the injection but did not cause a decrease blood
glucose levels in mice with severe hyperglycemia. The third injec-
tion of 40 U/kg at 180 min was sufﬁcient to decrease blood glucose
levels within 30 min of the injection. The reversion of hyperglyce-
mia started approximately 60 min after the insulin injection in
both mild and severe cases of hyperglycemia. In both cases, blood
glucose levels were rapidly elevated to an abnormal level (Fig. 3B).
This result conﬁrmed that the hyperglycemia was induced by
deprivation of plasma insulin caused by b cell depletion (see
Fig. 2B).
3.5. Hyperglycemia is cured by allogeneic transplantation of mouse
pancreatic islets and by xenogeneic transplantation of human
umbilical cord blood-derived cells
The DT-induced SCID-INS-TRECK-Tg hyperglycemic mice were
given the pancreatic islets of C57BL/6 via transplant beneath the
renal capsule. The blood glucose levels of these mice decreased
and reached normal levels (<200 mg/dl) 5 weeks after DT-adminis-
tration (Fig. 4A). This normal blood glucose level was maintained
for more than 15 weeks. DT-treated Tg mice that did not receive is-
let-transplantation maintained high glucose levels (>600 mg/dl).
This result indicated that the islet transplantation restored b cell
function in DT-treated Tg mice. Consistently, immunohistochemi-
cal analysis clearly showed that b cells within the transplanted tis-
sues generated insulin (Fig. 4B).
Then, we performed xenogeneic transplantation of human
umbilical cord blood-derived cells to the SCID-INS-TRECK-Tg mice
treated with DT. Human umbilical cord blood-derived cells were
divided into two groups: CD34+ and CD34 cells. CD34+ cells con-
tain stem cells that replenish pancreatic b cells [25,26]. Our preli-
minary results demonstrated that the transplantation of CD34+
cells recovered blood glucose to normal levels 70 days after trans-
plantation while the administration of CD34 cells did not cause
such an effect (Fig. 4C). This result indicated that the transplanted
CD34+ cells were able to differentiate into pancreatic b cells that
secreted insulin or that some factor(s) produced by the CD34+ cells
stimulated pancreatic b cell differentiation from its stem cells. This
should be clariﬁed by further experiments.A) Mice were transplanted with 200 islets from non-diabetic C57BL/6 inbred mice
planted islets (solid lines) and control mice that did not receive transplants (dashed
pper limit of the blood glucose meters, were indicated as 600 mg/dl. (B) The kidney
terstained with DAPI (blue). Scale bars represent 100 lm. (C) CD34+ or CD34 cells
Tg mice 7 days after DT administration. Blood glucose levels were measured at the
determined by Student’s t test. Asterisks represent statistical signiﬁcance (p < 0.05).
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We have generated two co-isogenic lines of ins-TRECK-Tg mice.
All of the lines developed hyperglycemia within 2 days of DT
administration (Fig. 1C). It is evident that hyperglycemia is caused
by the destruction of pancreatic b cells, which results in the severe
depletion of serum insulin (Figs. 2B and 3A). Furthermore, subcuta-
neous injection of recombinant insulin can cure hyperglycemia
when administered at sufﬁcient doses (Fig. 3B). An evident differ-
ence between Tg and non-Tg mice is their pancreatic morphology.
Namely, normal pancreatic islets consisted of approximately 80% b
cells surrounded by 20% of other cells, including a cells, while the
islets of Tg mice did not show such a systematic morphology;
rather, the a and b cells were randomly mixed and constructed
(Fig. 2B). This abnormality was observed in other ins-TRECK-Tg
mice, and we speculate that the growth hormone-like activity of
hDTR affects the pancreatic morphology of Tg mice. This possibility
will be proven by the use of mutated hDTR that lacks growth hor-
mone-like activity [23].
The decrease of blood glucose levels observed in SCID-INS-
TRECK-Tg mice 30 days after DT administration may be caused
by transdifferentiation of b cells according to the ﬁndings of Thorel
et al., who showed that b cells were transdifferentiated from a cells
after 1 month of DT administration when b cells were severely ab-
lated [4].
SCID mice can be transplanted with allograft and xenograft, and
thus are suitable for the development of regenerative therapies. To
establish this therapy for T1D, we performed allograft and xeno-
graft transplantation for DT-treated SCID-INS-TRECK-Tg mice to
cure hyperglycemia. When pancreatic islet cells were transplanted
beneath the renal capsule, the hyperglycemia of SCID-INS-TRECK-
Tg mice recovered 4–5 weeks after transplantation (Fig. 4A) while
SCID-INS-TRECK-Tg mice without transplantation maintained
hyperglycemia for 15 weeks. We conﬁrmed that the transplants
were engrafted in the subrenal capsule and contained functional
pancreatic b cells (Fig. 4B). This result clearly demonstrated that
engrafted b cells produced sufﬁcient insulin to recover hyperglyce-
mia in SCID-INS-TRECK-Tg mice and strongly suggests that blood
insulin levels were elevated.
Furthermore, we succeeded in curing hyperglycemia in SCID-
INS-TRECK-Tg mice through transplantation of CD34+ human
umbilical cord blood cells, which may contain stem cells for pan-
creatic b cells [27,28]. We speculate that engrafted CD34+ human
umbilical cord blood cells differentiated into pancreatic b cells in
the SCID-INS-TRECK-Tg mice and then secreted insulin into the
blood or that some factor(s) produced by the CD34+ human
umbilical cord blood cells stimulated to the differentiation of its
stem cell population into pancreatic b cells or the transdifferenti-
ation of a cells to b cells. The direct detection of human insulin in
the mouse serum will prove which of these processes are at play,
but this will be difﬁcult because the amino acid sequence of insu-
lin has little differences between humans and mice [29,30].
The reliance of BAC vector was, as expected, much better than
that of the plasmid vector. For example, one out of three of the
SCID-INS-TRECK-Tg mouse strains correctly expressed hDTR in
pancreatic b cells, while the other two strains ectopically expressed
the receptor and consequently died within 2 days after DT admin-
istration. By contrast, all four B6-ins2(BAC)-TRECK-Tg mouse
strains correctly expressed hDTR in b cells, although sensitivity
to DT differed among the strains. To carry out BAC-transgenesis,
we directly injected a supercoiled BAC clone into pronucleus-stage
eggs, and circular BAC clones were randomly cut and integrated
into nuclear genomes. However, the cut position seems hardly to
affect with reliance of transgene expression. Thus, it is evident that
BAC-transgenesis is superior to plasmid-transgenesis (Table 1).As mentioned in Figs. 1C and 4A,C SCID-INS-TRECK-Tg mice
lived for more than two months without insulin treatment. The
long survival of SCID-INS-TRECK-Tg mice has a great advantage
for research concerning the regeneration or recovery of b cell
functions.
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